Skip to main content
Premium Trial:

Request an Annual Quote

Underwriters Exercise Over-allotment Option on Thermo Fisher's $2.2B Public Offering

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that the underwriters of its recently announced $2.2 billion public offering of common stock have exercised their over-allotment option.

The underwriters purchased nearly 3.9 million additional shares of Thermo Fisher's stock at $85.50 per share in exercising the over-allotment option.

The company previously entered into forward sale agreements with affiliates of JP Morgan and Barclays with respect to the 25.7 million shares initially offered for sale. Thermo Fisher has also entered into additional forward sale agreements with respect to the 3.9 million shares exercised in the over-allotment option.

The affiliates of JP Morgan and Barclays are now expected to borrow from third parties and sell to the public through the underwriters a total of about 29.6 million shares of common stock in the offering, Thermo Fisher said.

Net proceeds from the offering will be used to fund a portion of the $13.6 billion acquisition of Life Technologies, anticipated to be completed in early 2014. The common stock offering is expected to close on or about June 12.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.